IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly.
暂无分享,去创建一个
P. Stenvinkel | R. Pecoits-Filho | B. Lindholm | T. Cederholm | M. Girndt | O. Heimbürger | M. Ketteler | Richard J. Johnson | M. Riella
[1] P. Stenvinkel,et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. , 2005, Kidney international.
[2] P. Stenvinkel,et al. POOR NUTRITIONAL STATUS AND INFLAMMATION: Novel Approaches in an Integrated Therapy of Inflammatory‐Associated Wasting in End‐Stage Renal Disease , 2004 .
[3] P. Stenvinkel,et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. , 2004, The American journal of clinical nutrition.
[4] A. Hishida,et al. Chlamydial infection and progression of carotid atherosclerosis in patients on regular haemodialysis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] W. Jeffcoate. Vascular calcification and osteolysis in diabetic neuropathy—is RANK-L the missing link? , 2004, Diabetologia.
[6] K. Kalantar-Zadeh,et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. , 2004, The American journal of clinical nutrition.
[7] I. Macdougall,et al. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. , 2004, Journal of the American Society of Nephrology : JASN.
[8] G. London,et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.
[9] K. Nitta,et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] P. D. De Deyn,et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. , 2004, Kidney international.
[11] S. Yusuf,et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. , 2004, Kidney international.
[12] L. Vernaglione,et al. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] Hongtao Zhang,et al. Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo* , 2004, Journal of Biological Chemistry.
[14] W. Zidek,et al. Acetylcysteine Reduces Plasma Homocysteine Concentration and Improves Pulse Pressure and Endothelial Function in Patients With End-Stage Renal Failure , 2004, Circulation.
[15] Shailendra Giri,et al. Potential Targets of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for Multiple Sclerosis Therapy , 2004, The Journal of Immunology.
[16] H. Drexler,et al. The Role of Interleukin-6 in the Failing Heart , 2001, Heart Failure Reviews.
[17] G. Gallagher,et al. A polymorphic dinucleotide repeat in the human IL-10 promoter , 2004, Immunogenetics.
[18] Paolo Raggi,et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.
[19] Wan-Wan Lin,et al. Statins induce suppressor of cytokine signaling‐3 in macrophages , 2003, FEBS letters.
[20] T. Naka,et al. Regulation of cytokine signaling by SOCS family molecules. , 2003, Trends in immunology.
[21] T. Toyo-Oka,et al. Inhibition of Hydroxymethylglutaryl-Coenzyme A Reductase Reduces Th1 Development and Promotes Th2 Development , 2003, Circulation research.
[22] Shuiping Zhao,et al. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[23] Y. Tintut,et al. Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[24] R. Detrano,et al. Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Mann,et al. Exercise training and skeletal muscle inflammation in chronic heart failure: feeling better about fatigue. , 2003, Journal of the American College of Cardiology.
[26] G. Schuler,et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. , 2003, Journal of the American College of Cardiology.
[27] T. Vary,et al. Effect of central administration of interleukin-1 receptor antagonist on protein synthesis in skeletal muscle, kidney, and liver during sepsis. , 2003, Metabolism: clinical and experimental.
[28] R. Wander,et al. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. , 2003, The Journal of nutritional biochemistry.
[29] P. Tipping,et al. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. , 2003, The American journal of pathology.
[30] T. Harris,et al. Insulin‐Like Growth Factor‐1 and Interleukin 6 Predict Sarcopenia in Very Old Community‐Living Men and Women: The Framingham Heart Study , 2003, Journal of the American Geriatrics Society.
[31] G. Boltz‐Nitulescu,et al. Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. , 2003, Biochemical and biophysical research communications.
[32] K. Yusoff,et al. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. , 2003, Atherosclerosis.
[33] C. Zoccali,et al. Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). , 2003, Kidney International.
[34] M. Odamaki,et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[35] P. Poole‐Wilson,et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. , 2003, The American journal of cardiology.
[36] M. Volpe,et al. Enhanced TNFα and oxidative stress in patients with heart failure: effect of TNFα on platelet O2 - production , 2003, Thrombosis and Haemostasis.
[37] G. Maurer,et al. Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway. , 2003, The Journal of infectious diseases.
[38] P. Stenvinkel,et al. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. , 2003, Journal of the American Society of Nephrology : JASN.
[39] S. Beddhu,et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. , 2003, Journal of the American Society of Nephrology : JASN.
[40] A. Hamsten,et al. TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease , 2003 .
[41] C. Dinarello. Anti-cytokine therapeutics and infections. , 2003, Vaccine.
[42] P. Stenvinkel,et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] R. Roubenoff. Catabolism of aging: is it an inflammatory process? , 2003, Current opinion in clinical nutrition and metabolic care.
[44] R. Fleischmann,et al. Addressing the safety of anakinra in patients with rheumatoid arthritis. , 2003, Rheumatology.
[45] C. Heeschen,et al. Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.
[46] G. Rice,et al. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. , 2003, The Journal of clinical endocrinology and metabolism.
[47] Abdissa Negassa,et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.
[48] C. Wanner,et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.
[49] J. Jankowski,et al. The Antioxidant Acetylcysteine Reduces Cardiovascular Events in Patients With End-Stage Renal Failure: A Randomized, Controlled Trial , 2003, Circulation.
[50] E. Ritz,et al. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. , 2003, Journal of the American Society of Nephrology : JASN.
[51] R. Vanholder,et al. In vitro study of the potential role of guanidines in uremia-related atherogenesis and infection , 2003 .
[52] J. Michel,et al. Interleukin-10 Deficiency Increases Atherosclerosis, Thrombosis, and Low-density Lipoproteins in Apolipoprotein E Knockout Mice , 2003, Molecular medicine.
[53] E. Falk,et al. Thalidomide inhibits early atherogenesis in apoE-deficient mice. , 2003, APMIS. Supplementum.
[54] J. Woo,et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. , 2003, Journal of the American Society of Nephrology : JASN.
[55] Johanna T Dwyer,et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. , 2002, The New England journal of medicine.
[56] H. Kirchner,et al. The interleukin-6 -174promoter polymorphism is associated with long-term kidney allograft survival. , 2002, Kidney international.
[57] J. Kjekshus,et al. Inflammatory imbalance between IL‐10 and TNFα in unstable angina potential plaque stabilizing effects of IL‐10 , 2002, European journal of clinical investigation.
[58] P. Flakoll,et al. Inflammatory signals associated with hemodialysis. , 2002, Kidney international.
[59] J. Bach,et al. The effect of infections on susceptibility to autoimmune and allergic diseases. , 2002, The New England journal of medicine.
[60] Sridevi Devaraj,et al. Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.
[61] P. Stenvinkel,et al. Review Articles: Inflammation in End‐stage Renal Disease: Sources, Consequences, and Therapy , 2002, Seminars in dialysis.
[62] H. Aburatani,et al. Peroxisome Proliferator-Activated Receptor Gamma Agonist Ligands Stimulate a Th2 Cytokine Response and Prevent Acute Colitis , 2002, Inflammatory bowel diseases.
[63] T. Georg,et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. , 2002, Kidney international.
[64] P. Stenvinkel,et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[65] J. Palmblad,et al. Captopril-impaired production of tumor necrosis factor-α–induced interleukin-1β in human monocytes is associated with altered intracellular distribution of nuclear factor-κB ☆ ☆☆ , 2002 .
[66] P. Stenvinkel,et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? , 2002, Kidney international. Supplement.
[67] Nancy G Kutner,et al. Association of fish intake and survival in a cohort of incident dialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[68] E. Vonesh,et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. , 2002, Journal of the American Society of Nephrology : JASN.
[69] K. Nitta,et al. Increased Serum Levels of Interleukin-12 May Be Associated with Th1 Differentiation in Hemodialysis Patients , 2002, Nephron.
[70] K. Preissner,et al. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[71] S. Anker. Imbalance of catabolic and anabolic pathways in chronic heart failure Implications for the treatment of cardiac cachexia , 2002 .
[72] S. Humphries,et al. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release , 2002, Heart.
[73] J. Schölmerich,et al. IL-10 therapy in Crohn's disease: at the crossroads , 2002, Gut.
[74] P. Stenvinkel,et al. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[75] M. Leinonen,et al. Evidence for infectious agents in cardiovascular disease and atherosclerosis. , 2002, The Lancet. Infectious diseases.
[76] S. Yusuf,et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.
[77] J. Kuiper,et al. Attenuation of atherogenesis by systemic and local adenovirus‐mediated gene transfer of interleukin‐10 in LDLr ‐/‐ Mice , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[78] M. Girndt,et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. , 2001, Kidney international.
[79] A. Kastrati,et al. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. , 2001, Atherosclerosis.
[80] J. Blacher,et al. Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal Disease , 2001, Hypertension.
[81] J. Kaski,et al. Serum Levels of the Antiinflammatory Cytokine Interleukin-10 Are Decreased in Patients With Unstable Angina , 2001, Circulation.
[82] A. Dal Canton,et al. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[83] C. Franceschi,et al. A gender–dependent genetic predisposition to produce high levels of IL‐6 is detrimental for longevity , 2001, European journal of immunology.
[84] J. Dwight,et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[85] J. Arnal,et al. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. , 2001, Atherosclerosis.
[86] M. Fukunaga. Pseudoangiomatous hyperplasia of mammary stroma: A case of pure type after removal of fibroadenoma Note , 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[87] Simon A. Jones,et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[88] S. Anker,et al. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.
[89] F. Parhami,et al. Tumor Necrosis Factor-&agr; Promotes In Vitro Calcification of Vascular Cells via the cAMP Pathway , 2000, Circulation.
[90] B. Jaber,et al. Interleukin-1 receptor antagonist synthesis by peripheral blood mononuclear cells: a novel predictor of morbidity among hemodialysis patients. , 2000, Journal of the American Society of Nephrology : JASN.
[91] B. Ames,et al. γ-Tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells , 2000 .
[92] M. Boaz,et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.
[93] C. Y. Wang,et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. , 2000, Science.
[94] M. McKee,et al. Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.
[95] T. Mizuochi,et al. Angiotensin‐converting enzyme inhibitor captopril prevents activation‐induced apoptosis by interfering with T cell activation signals , 2000, Clinical and experimental immunology.
[96] S. Fichtlscherer,et al. Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.
[97] M. Girndt,et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[98] P. Ridker,et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.
[99] D. Papanicolaou,et al. Interleukin-6: the endocrine cytokine. , 2000 .
[100] S. Humphries,et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.
[101] T. van der Poll,et al. Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. , 2000, The Journal of infectious diseases.
[102] I. Ebihara,et al. INTERLEUKIN-6 GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS UNDERGOING HEMODIALYSIS OR CONTINUOUS AMBULATORY PERITONEAL DIALYSIS , 2000, Renal failure.
[103] E. Keller,et al. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. , 2000, Annual review of medicine.
[104] K. Kataoka,et al. Serial circulating concentrations of c‐reactive protein, interleukin (il)‐4, and il‐6 in patients with acute left heart decompensation , 1999, Clinical cardiology.
[105] J. Palmblad,et al. Do ACE‐inhibitors suppress tumour necrosis factor‐α production in advanced chronic renal failure? , 1999, Journal of internal medicine.
[106] P. Sakkinen,et al. Interleukin-6 exacerbates early atherosclerosis in mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[107] M. Schuster,et al. Geriatric cachexia: the role of cytokines. , 1999, The American journal of clinical nutrition.
[108] P. Ganz,et al. Plasma α-Tocopherol and Coronary Endothelium-Dependent Vasodilator Function , 1999 .
[109] M. Pfeffer,et al. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .
[110] U. Andersson,et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. , 1999, Atherosclerosis.
[111] W. Mitch,et al. Mechanisms Causing Muscle Proteolysis in Uremia: The Influence of Insulin and Cytokines , 1999, Mineral and Electrolyte Metabolism.
[112] H. Cohen,et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.
[113] P. Stenvinkel,et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.
[114] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[115] Z Domljan,et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.
[116] R. Foley,et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[117] A. Falus,et al. Cytokine regulation of the acute‐phase protein levels in multiple myeloma , 1998, European journal of clinical investigation.
[118] D. Serur,et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[119] P. Kimmel,et al. Immunologic function and survival in hemodialysis patients. , 1998, Kidney international.
[120] J. Mege,et al. IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[121] R. Selgas,et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[122] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[123] P. Haslett. Anticytokine approaches to the treatment of anorexia and cachexia. , 1998, Seminars in oncology.
[124] Plata-Salamán Cr. Cytokines and anorexia: a brief overview. , 1998 .
[125] P. Wilson,et al. Monocyte cytokine production in an elderly population: effect of age and inflammation. , 1998, The journals of gerontology. Series A, Biological sciences and medical sciences.
[126] J S Yudkin,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .
[127] P. Vallance,et al. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. , 1997, Circulation.
[128] N. Kashihara,et al. Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. , 1997, Research communications in molecular pathology and pharmacology.
[129] H. Blom,et al. Genetic risk factor for unexplained recurrent early pregnancy loss , 1997, The Lancet.
[130] K. Tracey,et al. Fetuin protects the fetus from TNF , 1997, The Lancet.
[131] A. Finnegan,et al. Interleukin-10 inhibits interferon-gamma-induced intercellular adhesion molecule-1 gene transcription in human monocytes. , 1997, Blood.
[132] M. Feldmann,et al. Cytokine therapy in rheumatoid arthritis , 1996, The Lancet.
[133] C. Meisel,et al. Differential regulation of monocytic tumor necrosis factor‐α and interleukin‐10 expression , 1996, European journal of immunology.
[134] J. Friedman,et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. , 1996, The Journal of clinical investigation.
[135] H. Niiro,et al. Suppression of superoxide anion production by interleukin-10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase. , 1996, Experimental hematology.
[136] M. Yano,et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. , 1996, The Journal of clinical investigation.
[137] R. Roubenoff,et al. Mechanisms of loss of lean body mass in patients on chronic dialysis. , 1996, Blood purification.
[138] M. N. Marra,et al. Induction of interleukin-1 and interleukin-1 receptor antagonist during contaminated in-vitro dialysis with whole blood. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[139] J. Dayer,et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. , 1995, The Journal of clinical investigation.
[140] A. Brody,et al. Cytokine-binding proteins in the lung. , 1995, The American journal of physiology.
[141] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[142] Peng Wang,et al. Interleukin (IL)-10 Inhibits Nuclear Factor B (NFB) Activation in Human Monocytes , 1995, The Journal of Biological Chemistry.
[143] M. Girndt,et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. , 1995, Kidney international.
[144] P. Jungers,et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. , 1995, Journal of immunology.
[145] S. Zuckerman,et al. Endotoxin and GM‐CSF‐mediated down‐regulation of macrophage apo E secretion is inhibited by a TNF‐specific monoclonal antibody , 1994, Journal of leukocyte biology.
[146] M. Goodman. Interleukin-6 Induces Skeletal Muscle Protein Breakdown in Rats , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[147] M. Namiki,et al. Interleukin-8 in chronic renal failure and dialysis patients. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[148] D. Gouma,et al. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. , 1993, Journal of immunology.
[149] G. Strassmann,et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.
[150] C. Figdor,et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression , 1991, The Journal of experimental medicine.
[151] T. Bird,et al. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. , 1990, Cytokine.
[152] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[153] C. Dinarello. Cytokines and biocompatibility. , 1990, Blood purification.
[154] D. P. Strachan,et al. Hay fever, hygiene, and household size. , 1989, BMJ.
[155] T. Hirano,et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.
[156] R. Mattaliano,et al. Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. , 1987, Science.
[157] J. Hainsworth,et al. High-dose pilot studies in extensive-stage small-cell lung cancer. , 1986, Seminars in oncology.
[158] K. zum Büschenfelde,et al. Active hepatitis B vaccination of dialysis patients and medical staff. , 1984, Kidney international.
[159] J. Raoult,et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. , 1979, The Journal of clinical investigation.
[160] A. Matas,et al. INCREASED INCIDENCE OF MALIGNANCY DURING CHRONIC RENAL FAILURE , 1975, The Lancet.
[161] B. Scribner,et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.
[162] B. Scribner,et al. Cannulation of blood vessels for prolonged hemodialysis. , 1960, Transactions - American Society for Artificial Internal Organs.